Episcleritis is a self limiting inflammatory disease requiring no treatment provided it does not become recurrent or develop associ ated scleral inflammation. The disease pro cess is therefore a suitable model for the initial clinical assessment of the efficacy of new anti inflammatory preparations. 1 It has two dis tinct clinical forms and may be simple or nod ular. 2,3,4 The severity and duration of individual attacks is highly variable, but the condition itself is often sufficiently uncomfortable that many patients require some form of anti-inflammatory preparation. Topical steroids are commonly used and their efficacy for this condition is well known,5,6.7 but these sometimes induce side-effects including a rise in intraocular pressure and cataract formation especially with prolonged use. These side effects are particularly rele vant in recurrent episcleritis.
The search for alternative forms of treat ment for ocular inflammation is a continuing process and most published work has been done on non-steroidal anti-inflammatory drugs (NSAIDS) . 1 . 5 . 7 -1 0 Double-blind studies using both systemic9 and topical oxyphenbu tazone5 have shown that this agent is effective in reducing the inflammation in episcleritis. This drug is not satisfactory for routine use because the oral preparation has multiple side effects and topical treatment has to be used as an ointment. 5 Although systemic flurbipro fen4,1l is effective in the treatment of episcler ItlS, topical treatment has little anti-inflammatory effect. 7 The aim of this study is to determine the effectiveness of 2-(2-Hydroxy-4-methylphe nyl) Aminothiazole Hydrochloride (CBS 113A) 0.1% drops, a new anti-inflam matory agent, for the treatment of episcler-itis. The pharmacological profile of CBS 113A is unique: it is a dual inhibitor of both cyclo-oxygenase and lipoxygenase, as well as being a potent free-radical scavenger.
12.13,14

Materials and Methods
Patients
A randomised double blind trial was carried out at the Casualty Department of Moorfields Eye Hospital, London. Forty-three consec utive cases of episcleritis were recruited (38 patients including four patients with bilateral disease and one patient with two separate attacks) which were either first or 'fecurrent attacks, Patients already on treatment with steroids or NSAIDS were excluded. Cases were randomly allocated to one of two groups. Patients allocated to the drug group (G. drug) were given CBS 113A 0.1 % to be instilled one drop six times a day for the first week and four times a day for a further two weeks. This regime was suggested by Labora toire Chauvin, based on results obtained from previous studies.15 •16 Patients in the placebo group (G. placebo) received the vehicle of the eye drops only, in a similar fashion. Neither the patients, surgeons or the pharmacists had any knowledge of the randomisation until the trial was completed. The study had the approval of the Hospital Ethical Committee and the informed written consent of all the patients.
Drug
The already randomised preparations of CBS 113A were provided by Laboratoire 
Parameters of assessment
At the initial attendance (Day 0 = DO), the severity of the episcleritis was assessed in terms of pain, conjunctival and episcleral injection, and the presence of nodules. Pain was graded subjectively and scored as being absent (0), mild (1), moderate (2) or severe (3) . Conjunctival and episcleral lllJection were scored for each quadrant of the 'white of the eye' using the following scale: absent (0), very mild (0.5), mild (1), moderate (2) or severe (3) . The presence of nodules were noted and each nodule received a score of three. The numerical sum of the above four parameters is the total score (TS) and gives an indication of the severity of the episcleritis. A full ocular and medical history was taken, including the duration of the current attack prior to presentation (duration of illness) and whether the attack was the first or a recurrence.
Cases were reassessed using the above four parameters on Days 3 (D3), 7 (D7), 14 (DI4) and 21 (D21). In addition, the intraocular pressure was measured on each occasion. Any untoward side effects were recorded. In par ticular, enquiries were made about stinging on instillation of the eye drops (Absent (0), mild (1), moderate (2) and severe (3)). Patients who deteriorated clinically were withdrawn from the trial and were treated with predniso lone 0.3% eye drops and oral flurbiprofen for two weeks. Patients were assessed by the same surgeon (CSCL) throughout the study.
Statistical analysis
The following statistical tests were applied:
Age of patient and duration of illness with the t-test for independent samples. Sex of the patient, history of allergies, whether first attack or recurrence, type and severity of the episcleritis with the Chi square tabulation test.
Pain score and stinging score with the Mann-Whitney U test within and between groups. Conjunctival and episcleral injection, nod ules, total score and intraocular pressure by One way analysis of variance. The percentage of patients free from inflammatory signs (i.e. conjunctival and episcleral injection and nodules) was also analysed by the Chi-square tabulation test. Data were considered different when the statistical significance value was <0.05.
Results
Of the 43 eyes of 38 patients, 20 were allo cated to G. placebo and 23 to G. drug. Thirty- (Table I) . Data from these seven patients were included in the analysis until the point of withdrawal. The effects of drug treatment versus pla cebo were compared in all patients and in two sub-groups as follows:
(1) All patients: 20 patients from G. placebo and 23 patients from G. drug. (2) Mild episcleritis: any patient with an initial total score of less than 15. This group con sisted of 10 patients from G. placebo and 12 patients from G. drug. (1) Severe episcleritis: any patient with an initial total score of 15 or more. This group consisted of 10 patients from G. placebo and 11 patients from G. drug.
All Patients
There was no significant difference between the age, sex, duration of illness, type and sev erity of the episcleritis and whether it was the first or a recurrent attack, although patients in the placebo group were younger (33. 4 years c.£. 38. 52 years, p = 0. 13) and had a higher proportion of patients presenting with their There was no difference in outcome between the two groups in terms of the mean total score, pain score, mean scores of con junctival and episcleral injection, and mean score for nodules. However within each group, there was a significant reduction in pain comparing D7, D14 and D21 with DO in both groups, and also D3 with DO in the pla cebo group. A higher percentage of cases in the drug group were free from conjunctival and episcleral injection but statistical signifi cance was not reached (Fig. 1) .
Bilateral cases
Four patients had bilateral disease. Two of these received different treatment to each eye (placebo eye drops to one and CBS 113A eye drops to the other). Both these patients were convinced that the two eyes were treated dif ferently, complaining of stinging on instill ation of the active drug. With the other two patients, both eyes were treated with th e active drug (Table II) .
Recurrent case
One patient (W4, active drug and placebo eye drops in the same eye during separate attacks. During his first attack, he was treated with placebo drops and he was withdrawn from the trial because of clinical deterioration. He developed a recur rent attack having been without symptoms and signs for one week. He was re-entered into the trial and was on the second occasion allocated to the active drug group. He went through the whole trial on this occasion and the score decreased from 7 at DO to 1.S at D21.
Side Effects
Stinging was reported by 20123 (86.9%) of patients treated with the active drug but only by 7/20 (3S%) of patients in the placebo group. All patients on the active drug who complained of stinging reported moderate to severe stinging whereas none of the patients on placebo reported severe stinging. Intra ocular pressure: there was no significant vari ation along the study in either group. In addition, the intraocular pressure remained under 21 mm Hg in all patients throughout the study.
Other untoward reactions
Placebo group:
One patient developed a small subconjunc tival haemorrhage.
Drug group: One patient developed lower lid oedema at D7 which disappeared by D21, and granu larity of the corneal epithelium at D14 which also disappeared by D21. This patient had a history of allergy to aspirin and co-trimoxazole. One patient developed cheek oedema at D3 which gradually decreased and dis appeared by D21. In this case there was no history of allergy to medications.
Mild Episcleritis
Patients in the drug group were on average older (37.08 years c. f. 30.9 years, p = 0.121), had shorter duration of illness prior to presen tation (3.4 days c. f. 11.7 days, p = 0.08) and a higher proportion of patients with simple epi scleritis (92% c. f. 70%, P = O.4S). Patients in the placebo group had a higher proportion of patients presenting with their first attack (90% c. f. SO%, P = 0.12). These differences were not statistically significant. The evolution of the averaged total scores, and scores for" conjunctival and episcleral injection of the drug and placebo groups ' are shown in Figs The percentage of patients free from con junctival and episcleral injection were higher in the drug treated group but statistical signifi cance was not achieved (Fig. 4) .
Severe Episcleritis
The characteristics of the patients in the drug group and the placebo group were compar able. There were no differences in outcome (mean total scores, scores for pain, conjunc tival injection, episcleral injection and for nodules) of the two groups.
Discussion
The anti-inflammatory activity of the majority of NSAIDS is primarily attributed to inhibi tion of distinct steps in the arachidonic acid cascade, particularly the cyclo-oxygenase pathway. 1 7 2-(2-Hydroxy-4-methylphenyl) Aminothiazole Hydrochloride (CBS 113A) is unique in that it is a dual inhibitor of both cyclo-oxygenase and lipoxygenase as well as being a free radical scavenger. 1 2-1 4 From arachidonic acid, cyclo-oxygenase activity leads to the production of prostaglandins whereas the lipoxygenase pathway leads to the production of leukotrienes. Free radicals are generated at sites of inflammation by leu kocyte phagocytosis and by the presence of ischaemia-reperfusion injury. 18 Prosta glandins, leukotrienes and free radicals are all mediators of inflammation. 19 Glucocorticoids are potent anti-inflamma tory agents. They exert some of their effects by inhibiting the enzyme phospholipase A thus preventing the release of arachidonic acid from membrane phospholipids. By act ing at a higher level than NSAIDS, glucocorti coids decrease the synthesis of both prostaglandins and leukotrienes. The effects of CBS 113A therefore closely mimic those of glucocorticoids in that it inhibits both the cyclo-oxygenase and lip oxygenase pathways while ordinary NSAIDS inhibit the cyclo-oxy genase pathway only.17 This dual inhibition is a real advantage in controlling inflammation as many NSAIDS actually increase leukotri ene production by diverging arachidonic acid metabolism to the lipoxygenase pathway.
19.20
The pharmacological activity of CBS 113A has been shown both in vitro l2 and in viVO. 1 3-1 6 It was shown to inhibit cyclo-oxygenase activ ity in platelets and 5-lipoxygenase activity in leukocytes. In addition its free radical scav enging activity was demonstrated. CBS 113A was also shown to inhibit oxygen burst in stimulated leukocytes and the release of Interleukin I-like compound from vascular endothelial cells in culture. 1 2 In vivo, it inhibited inflammation in experimental con junctivitis and uveitis induced by various agents. The experimental animals were mostly pre-treated with the drug before the insult. It was also shown that CBS 113A did not have a worsening effect on experimental herpetic keratitis. CBS 113A was devoid of any anti-inflammatory activity when admin istered orally. Because of a very short half-life in plasma, it would not be suitable for intra venous administration either. 13 Preliminary clinical studies on patients with 'acute con junctivitis' (of allergic and viral "aetiology )15 and post-cataract extraction patients16 have shown CBS 113A to be effective in reducing ocular inflammation. No toxic effect to the epithelium was reported.
We have shown CBS 113A to be effective in reducing the signs of inflammation within the first week of administration of the drug in mild but not severe episcleritis. The differences were significant at D3 (Total score p = 0.0013; Conjunctival injection p = 0.017; Episcleral injection p = 0.0018) and D7 (Total score p = 0.01; Conjunctival injection p = 0.014; Episcleral injection p =0.027), but not on Days 14 and 21. That significant values were not achieved at D14 and D21 can be explained by the self-limiting nature of the disease. The percentage of patients free from conjunctival and episcleral injection were also higher in the drug treated groups although statistical significance was not achieved (Figs. 1 and 4 ). Given such a broad pharmac ological profile, it was surprising that CBS 113A was not effective against severe episcleritis as well. This might have been due to a number of reasons.
Comparing the severity of the episcleritis of our patients with those in previous studies with nearly identical scoring system, our patients had particularly severe disease. Our mean initial total score for the drug group . In fact, most of the patients from the studies quoted would have been mild disease by our definition, and would probably have done as well with CBS 113A as with ste roids. It may be that more frequent instill ation of CBS 113A is necessary for severe disease. A higher concentration of CBS 113A may also be of help, especially if the con junctiva and episclera are much thickened.
We initially suspected that early treatment may be necessary for a good therapeutic response. In the mild episcleritis sub-group, CBS 113A was very effective in rapidly reduc ing inflammation. The drug treated group had a much shorter history (3.4 days) than the pla cebo group (11.7 days) prior to presentation (p = 0.08), nearly reaching statistical signifi cance. However, on plotting a graph of the efficacy of CBS 113A against the duration of illness of all our patients (not shown), no such relationship could be shown.
Lack of compliance is a possible reason for a poor response but we do not believe this to be the case. Compliance was always enquired for at each follow up visit. None of the patients except one admitted to non-comrli ance. This patient used his eye-drops two or three times a day instead of four times a day for one week because it was inconvenient to instill eye-drops at work.
All the cases withdrawn from the CBS 113A treated group had severe disease to begin with. This is in contrast to patients withdrawn from the placebo group with three out of the four patients presenting with mild disease. We would agree with Lyons7 that some cases of episcleritis do progress to scler itis. The possibility of progression was noted earlier by Duke-Elder. 21 It is conceivable that CBS 113A may have prevented such progres sion of initially mild disease.
Stinging from CBS 113A is a feature of the compound. Stinging was reported by 20/23 (86.9% ) of patients treated with the active drug but only by 7120 (35% ) of patients in the placebo group .. In addition, patients with bilateral disease treated with CBS 113A in one eye and placebo in the other complained of quite significant but short-lived stinging from what turned out to be the active drug. Although non-compliance has not been a problem with our study patients, stinging may contribute to non-compliance in less commit ted patients. A change in formulation may help. Reducing the need to instill frequently will also help with compliance.
CBS 113A did not cause any significant variation in intraocular pressurt: .. None of our patients had an intraocular pressure of over 21 mm Hg at any time. This is important as prostaglandins are increasingly recognised to have a regulatory effect on intraocular pressure. 20, [22] [23] [24] The corneal epithelial irregularity in one of the patients treated with CBS 113A may just have been part of the disease, rather than a side effect of the drug, as corneal involvement occurs in 15% of patients with episcleritis. 3 One patient developed lower lid oedema and another developed cheek oedema. Both patients completed the trial with spontaneous resolution of the oedema, making an allergic type rection to the drug extremely unlikely.
Given our results, we would recommend the use of CBS 113A for the treatment of mil der cases of episcleritis. Rapid relief of con gestion in the conjunctiva and episclera would benefit the patient enormously as it is the red ness of the eye which patients with episcleritis so often complain of. CBS 113A would also be of help with frequent bouts of attacks, being free from the serious side-effects of ste roids eye drops. By the same argument, a trial of CBS 113A may be worthwhile in known steroid responders and in patients with a history of herpetic keratitis, even if the epi scleritis is severe.
CBS 113A may by its own actions comple ment steroids and thus have a steroid sparing effect. This is the case with diclofenac-sodium drops! and with sodium cromoglycate in the treatment of vernal keratoconjunctivitis. 25 Its action as a free radical scavenger may also be of help in alkali burns and in uveitis. 2 6 Further studies will be required in these areas.
